Price
CHART BY
Frequently asked questions
What is Summit's market capitalization?
The market capitalization of Summit is $17.31B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Summit?
Summit's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.308. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Summit's stock?
Currently, 9 analysts cover Summit's stock, with a consensus target price of $36.88. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Summit?
Summit's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$211.20M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Summit?
Summit has a free cash flow of -$142.66M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Summit have, and what sector and industry does it belong to?
Summit employs approximately 159 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Summit's shares?
The free float of Summit is 111.14M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $17.31B
- EPS (TTM)
- -$0.308
- Free Float
- 111.14M
- EBITDA (TTM)
- -$211.20M
- Free Cashflow (TTM)
- -$142.66M
Pricing
- 52W span
- $2.105$36.91
Analyst Ratings
The price target is $36.88 and the stock is covered by 9 analysts.
Buy
9
Hold
0
Sell
0
Information
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
- Employees
- 159
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US86627T1088
- Primary Ticker
- SMMT
Fundamentals & EOD data from FactSet